Fig. 3 | Signal Transduction and Targeted Therapy

Fig. 3

From: Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT

Fig. 3

Outcomes of r/r aggressive B-cell cases stratified by four functional classification systems of TP53 alterations after CAR19/22 T-cell infusion. In individuals with r/r aggressive B-cell lymphoma and concurrent TP53 mutations, PFS (a, c and e) and OS (b, d, and f) were compared according to functional classifications of TP53 mutations. Kaplan–Meier analysis of PFS (a) and OS (b) for the non-missense and missense mutation groups. Kaplan–Meier analysis of PFS (c) and OS (d) for the non-disruptive and disruptive mutation groups. Kaplan–Meier analysis of PFS (e) and OS (f) for EAp53 low-risk (<75) and EAp53 high-risk (≥75) mutation groups. Kaplan–Meier analysis of PFS (g) and OS (h) in the del(17p) and non-del(17p) groups

Back to article page